Shares of HLS Therapeutics Inc. (TSE:HLS - Get Free Report) fell 1.2% on Thursday . The stock traded as low as C$4.17 and last traded at C$4.20. 19,500 shares changed hands during mid-day trading, an increase of 34% from the average session volume of 14,595 shares. The stock had previously closed at C$4.25.
Analysts Set New Price Targets
Separately, Stifel Nicolaus lifted their price target on HLS Therapeutics from C$3.50 to C$4.00 and gave the company a "hold" rating in a report on Wednesday, March 26th.
Get Our Latest Research Report on HLS
HLS Therapeutics Stock Down 0.9 %
The company has a current ratio of 1.56, a quick ratio of 1.01 and a debt-to-equity ratio of 86.50. The business's fifty day moving average price is C$4.24 and its two-hundred day moving average price is C$3.92. The firm has a market cap of C$93.66 million, a P/E ratio of -4.22 and a beta of 1.07.
HLS Therapeutics Company Profile
(
Get Free Report)
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.
Further Reading
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
